Singapore markets closed

Straits Times Index
3,255.54
+16.51(+0.51%)
S&P 500
3,963.76
-13.77(-0.35%)
Dow
32,447.94
+15.86(+0.05%)
Nasdaq
11,668.88
-99.95(-0.85%)
Bitcoin USD
26,967.74
-418.18(-1.53%)
CMC Crypto 200
590.64
+347.96(+143.38%)

AZN Jul 2023 90.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.1000

0.0000

(0.00%)

As of 12:08PM EDT. Market open.

Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.